Pharmaceutical and Biotechnology companies are increasingly required to gather concise knowledge on the characteristics of a given compound with fewer clinical trials at a much early stage. This is to reduce the time taken to decide on the continuation on the development strategy. This is fundamental for both the scientific and economic justifications.
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settings